JAMP Pentoxifylline SR 400mg: Affected lot may contain Sitagliptin 100mg tablets.
Brand(s)
Last updated
Summary
Product
JAMP Pentoxifylline SR
Issue
Health products - Product safety
What to do
Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot |
|---|---|---|---|---|---|
| JAMP | JAMP Pentoxifylline SR | DIN 02543087 | Tablet (Extended-Release) | Pentoxifyllin 400mg | P3824001F |
Issue
Affected lot may contain Sitagliptin 100mg tablets
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
JAMP Pharma Corporation
1310 Rue Nobel,
Boucherville, QC,
J4B 5H3
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type III
Identification number
RA-77404
Get notified
Receive emails about new and updated recall and safety alerts.